Replimune Group Inc. Common Stock is a biotechnology company focused on the development of oncolytic immunotherapies for the treatment of cancer. Their innovative platform combines oncolytic viruses with immune activating transgenes, aiming to enhance antitumor immune response and improve patient outcomes. With a broad pipeline and strong partnerships, Replimune is poised to make a significant impact in the field of immuno-oncology.
